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ABSTRACT 
 Angiogenesis is the process of developing and elongating blood vessels.  In obesity, 
angiogenesis controls the development of the adipose tissue, allowing it to expand as energy 
stores increase.  When angiogenesis is blocked in rodent models, adipose tissue not only stops 
expanding, but regresses, proving a possible mechanism for weight loss.  Nt, a Chinese herbal 
decoction, and gallic acid, an active antiangiogenic ingredient in Nt, were tested in clinical trials 
in combination for possible use as a supplement for weight loss.  The Nt-gallic acid combination 
did not cause weight loss or a decrease in food intake in humans, principally due to the inability 
to achieve adequate serum levels.  The highest absorption seen was 19% of 800mg gallic acid, 
far below the level needed to cause weight loss.  In further research, gallic acid was tested in 
combination with colchicine, a tubulin inhibitor.  This combination was hypothesized to act 
synergistically in an in vitro assay to inhibit angiogenesis.  The combination inhibited 
angiogenesis 91% compared to the control, while the addition of the two compounds separately 
led to an 81% inhibition.  In addition, pilot data shows that this combination, when added to a 
cream base, may aid in the treatment of psoriasis.  These studies suggest that gallic acid is 
capable of inhibiting angiogenesis in humans when adequate therapeutic levels are reached. 
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CHAPTER 1 
INTRODUCTION 
Obesity, defined as excess body fat, is gaining prevalence around the world. The 
estimated direct and indirect costs of obesity are nearly $100 billion in the United States 
(Williamson et al., 1998).   As of 2002, approximately 65% of adults in the US over the age of 
20 were either overweight or obese; likewise, 31% of children between the ages of 6 and 19 were 
either overweight or obese (Hedley et al., 2004).  The largest increases were seen in class III 
obesity, classified by a body mass index (BMI) of greater than 40 (Freedman et al., 2002).  In 
addition, obesity is more common in the lower socio-economic classes (Freedman et al., 2002; 
Roberts et al., 2004). 
Behavioral, environmental, genetic, and metabolic factors all contribute to the linear 
increase in the prevalence of obesity (Lyznicki et al., 2001).  This rising occurrence of obesity is 
the result of thousands of years of genetic evolution toward a thrifty use of energy, combined 
with labor-saving technology, the availability of food to serve psychological needs, and an 
increased energy density of the foods we consume.  Although all of these factors have a link to 
obesity, other factors may still remain undiscovered.  As research continues to expand our 
knowledge, we will continue to absorb the cost of obesity until an effective treatment is 
identified. 
Obesity increases the risk of developing other diseases that contribute to this health crisis.  
Excess adipose tissue is associated with insulin resistance and an increase in risk factors for 
coronary artery disease.  This type of heart disease is associated with dysfunction of endothelial 
cells in response to inflammatory signals.  Adipose tissue secretes many adipokines in proportion 
to its mass which promote this inflammatory response.  These include TNFα, IL-6, leptin, CRP, 
PAI-1, resistin, and angiotensin (Lau et al., 2005).   
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Coronary artery disease and obesity are also associated with high triglycerides, low HDL 
cholesterol, and small, dense LDL particles (Bray, 2004).  Another condition that is closely tied 
to coronary artery disease and obesity is hypertension.  Hypertension increases the workload of 
the heart, thickens the ventricular wall, and leads to congestive heart failure (Bray, 2004).   
Gallbladder disease is yet another major risk attributed to obesity.  Obesity is associated with 
increased cholesterol turn-over resulting in supersaturated bile and the potential to precipitate 
into gallstones (Bray, 2004).   
Perhaps the most well known disease related to obesity is type 2 diabetes mellitus.  The risk 
of developing diabetes continues to increase the longer a person is obese, and also with the 
central distribution of fat (Bray, 2004).  As previously discussed, this is due to insulin resistance 
resulting from a higher level of fatty acids circulating in the blood.  These fatty acids are 
eventually stored in the liver and muscle as part of the insulin resistance process. 
Other manifestations of cardiovascular disease originate from the metabolic disorders that 
accompany obesity.  There is a strong correlation between obesity and a number of different 
forms of cancer, including cancer of the colon, prostate, gallbladder, and breast (Bray, 2004).  
Although insulin and IGF-1 are growth factors elevated in obesity thought to be related to the 
increased risk of cancer in the obese, increased estrogen due to aromatization in fat tissue may 
also play a role in endocrine related cancers such as cancer of the breast. 
There are also several disorders stemming from excess adipose tissue related to the amount 
of weight the body must carry in an obese state.  One of these is a type of sleep apnea, which is 
caused in the obese by an increase in pressure on the lungs due to the larger amount of fat in the 
abdomen, which displaces the diaphragm further into the chest cavity (Bray, 2004).  In chronic 
situations this would also lead to other respiratory problems due to the lungs’ inability to expand 
and contract properly.   
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Likewise, osteoarthritis is another mechanical problem caused by obesity.  A strong 
correlation has been shown between increasing weight and joint problems due to osteoarthritis 
(Felson et al., 1988).  Since many nonweight-bearing joints also display increased osteoarthritis, 
weight may be only one of many factors contributing to this disease. 
 The current recommendations for treating obesity involve an initial weight loss of 5-10% 
followed by 1-2 pounds of weight loss per week until a suitable maintenance goal has been 
achieved.  This plan consists of dietary therapy, increased physical activity, behavior 
modification, in moderate cases pharmacotherapy, and in extreme cases surgery (Lyznicki et al., 
2001).  Therapeutic drugs and effective herbal supplements are useful tools to decrease food 
intake and increase energy expenditure, and several other methods of treating overweight and 
obesity are now being explored as well (Greenway et al., 2005a; Roberts et al., 2005a; Roberts et 
al., 2005b; Roberts et al., 2005d).  Inhibiting angiogenesis, the process of developing and 
elongating blood vessels, is one of these promising methods that is being explored for facilitating 
weight loss. 
Angiogenesis 
 Angiogenesis plays an important role in all tissues during development, from the 
formation of the fetus during early development through adolescence in humans.  Once the 
body’s major phase of growth has ended, angiogenesis is only seen in a few instances.  These 
include wound healing, menstruation in females of child-bearing age, cancer growth, the adverse 
formation of excessive vasculature seen in the retinopathy, and in other angiogenesis driven 
diseases including obesity (Folkman, 1982).  The capability of adipose tissue to be dynamic in 
size is an exception, since few other tissues are capable of altering size through angiogenesis.   
Adipose tissue must be able to grow and recede based on the availability of and need for 
fat by peripheral tissues such as skeletal muscle.  This dynamic endocrine relationship regulates 
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the disposition of the adipose tissue as an entire mass.  When energy intake surpasses the energy 
demand of the body, the size of the mass increases.  Conversely, when the body signals a need 
for the release of these fatty acids, the size of the tissue diminishes as the fat droplets release 
fatty acids into the blood.  Each of these situations will be examined in more detail from a 
vascular perspective. 
Folkman, who was studying the growth of cancerous tumors, noted that these tumors 
were unable to grow past approximately two millimeters in diameter without angiogenesis 
initiating additional blood supply (Folkman, 1982).  The same holds true in adipose tissue (Neels 
et al., 2004).  As the adipocytes begin to swell with lipids in a storage mode, there is a barrier 
beyond which the cell can no longer expand.  This calls for the development of new adipocytes 
from preadipocytes, which will need an adequate blood supply to provide nutrients to the cells 
and an adequate vascular network to send fatty acids to peripheral tissues. 
This process occurs through a complex system of paracrine signals and environmentally 
related hypoxic conditions.  Acting in tandem, these conditions promote the formation of new 
adipocytes and endothelial cells from stem cell precursors.  This process is amplified by 
adipocyte metabolism and hormone secretion (Lolmede et al., 2003).   
Hypoxia, a lack of oxygen within a tissue, increases the acidity of the interstitial fluid.  
This acidosis induces angiogenesis due to the lack of adequate vasculature within transplanted 
fat pads in mouse experiments (Neels et al., 2004).  When the fat pads are transplanted, a 
necrotic core rapidly develops that continues radially from the center of the pad until adequate 
angiogenesis has occurred.  At this point the necrosis is replaced by reforming adipocytes and 
connective tissue. 
It has been hypothesized that this same process occurs on the outskirts of a developing 
adipose tissue mass as the adipocytes signal the growth mechanism (Crandall et al., 1997).  
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Minute changes in oxygen and nutrient availability spawn the release of pro-angiogenic 
adipocytokines that may recruit endothelial cells to expand the preexisting vasculature (Planat-
Benard et al., 2004).  Another hypothesis asserts that endothelial cells are signaled to develop 
new vessels, and this process initiates the transformation of preadipocytes into adipocytes 
(Hausman and Richardson, 2004). 
It is currently unclear as to the order in which this process occurs, and multiple studies 
have been published that support conflicting mechanisms (Fukumura et al., 2003; Hausman and 
Richardson, 2004).  There is some evidence however that the answer to this question may 
depend on the fat depot location and the stage of development.  During fetal development, it is 
clear that angiogenesis predates adipocyte differentiation (Crandall et al., 1997).  This comes as 
no surprise, since a vascular structure must be established before appreciable development can be 
seen. 
After adolescence, however, the mechanism becomes more difficult to determine.  It 
appears that the location of the adipose tissue will influence which process initiates the other, but 
more research is needed in order to clearly define this relationship (Neels et al., 2004).  In any 
event, an increase in dietary fat in the blood that surpasses the body’s demand will be stored by 
the adipocytes, and an expanded vasculature must be made to accommodate it. 
All of the primary cells needed to fuel this vascular reaction appear to reside within the 
stroma-vascular structure of adipose tissue (Miranville et al., 2004).  This stroma-vascular 
fraction seems to hold the precursors to both the endothelial cells and the adipocytes.  There is 
also some evidence that the adipocytes themselves can digress towards the progenitor cells and 
actually redifferentiate into endothelial cells (Planat-Benard et al., 2004).  This remarkable 
capability seems to be localized to white adipose tissue, as brown adipose tissue is not capable of 
the same transformation. 
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When adipocytes are placed in a culture conducive to vascular growth, they lose fatty 
acids, change their morphology to a more preadipocyte- like structure, and become a fibroblast-
like cell that attaches to a coverslip (Planat-Benard et al., 2004).  The cells then lose the 
enzymatic characteristics of adipocytes that promote lipolysis, lipogenesis, and adipocyte 
molecular marker expression.  When these cells are cultured in a cellular matrix, they form 
branched alignments and display markers normally present on endothelial cells (Planat-Benard et 
al., 2004).  Most importantly, these cells do not show the markers of circulating endothelial cells 
that are derived from macrophages or monocytes, proving that they reside within the adipose 
tissue. 
These endothelial cells, when activated, stimulate revascularization when introduced into 
the mouse ischemic hind limb model, and this process shows a strong positive correlation with 
BMI (Miranville et al., 2004; Planat-Benard et al., 2004).  Eventually, additional endothelial 
cells are recruited from other areas to the hypoxic conditions, and this response allows the 
adipocytes to develop and multiply more rapidly. 
The development of endothelial cells can take one of two paths, and it has not until 
recently been clear which is employed in adipose tissue.  One route is by the process of 
angiogenesis as described above.  The other is by a process called neovascularization, which is 
the recruitment of circulating endothelial cell precursors to the site of new blood vessel 
formation (Neels et al., 2004).  The distinction between the two, although seemingly trivial, is of 
paramount importance.   
The concept of neovascularization would imply a systemic effect of hypoxia induced 
factors within the body as a whole, but this does not seem to be the case.  Neovascularization 
functions on the broad basis of tissue injury or more localized vastly affected hypoxic and anoxic 
tissues (Neels et al., 2004).  Neovascularization is supplemented by endothelial precursor cells 
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that circulate in the peripheral blood.  These cells, once recruited to the site of injury, will rapidly 
divide to form new vessels, causing an immense chain reaction of vascularization. 
Angiogenesis, in contrast, appears to work in adipose tissue on a much more localized 
basis, secreting factors that recruit the nearest vasculature to multiply and divide.  Angiogenesis 
results in a much more controlled and precise method of vascular growth since only the nearest 
cells are affected.  This was shown to be the primary mechanism in adipose tissue growth by 
immunofluorescent staining for endothelial progenitor cells, which was overwhelmingly negative 
in the vasculature of the adipose tissue (Neels et al., 2004). 
Since it is now known that angiogenesis plays a vital role in the expansion of adipose 
tissue, the potential to inhibit this process can play a major part in preventing weight gain and 
promoting weight loss.  The traditional method of reducing the fat mass involves decreasing 
caloric intake so the body has to use its fat stores to maintain energy expenditure level.  The 
increasing prevalence of obesity during the last twenty years in the face of national goals to 
decrease its prevalence is a testimony to the ineffectiveness of this dietary approach to treatment.  
Inhibiting angiogenesis rather than limiting calories may be more effective since adipose tissue is 
incapable of receiving an adequate oxygen supply if angiogenesis is inhibited. 
There have been many potent angiogenesis inhibitors used in rat and mouse studies to 
date.  One of the most effective angiogenesis inhibitors in mice is TNP-470.  It does not seem to 
produce any adverse side effects in rodents and appears to affect metabolism and food intake 
rather than behavior (Brakenhielm et al., 2004). 
Leptin deficient ob/ob mice treated with TNP-470 show a decrease in weight and BMI 
over a 12 week period (Brakenhielm et al., 2004).  This decrease is due to a lack of adipose 
tissue development with growth but no muscle loss at autopsy.  Even more interesting, mice 
treated with TNP-470 had a significant decrease in body weight and BMI compared to pair- fed 
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controls.  This loss of body weight came from subcutaneous and omental fat depots, and seemed 
to not affect muscle tissue. 
Since most cases of obesity in our society, unlike ob/ob mice, are not related to an 
autosomal recessive mutation, wild type mice have also been studied with TNP-470 
administration in combination with a high fat diet (Brakenhielm et al., 2004).   The treated mice 
decreased subcutaneous, omental, and perigonadal fat depots, but had no change in food intake 
or basal resting metabolic rate.  The only significant change was seen in total cholesterol, LDL 
cholesterol, triglycerides, and serum insulin, all of which decreased.  In both the ob/ob and wt 
mouse studies, the TNP-470 groups reduced vascularization within the fat pads, and the average 
volume of the adipocytes decreased approximately 10-fold.  Smaller fat cells are associated with 
improved insulin sensitivity and decreased risk of developing type 2 diabetes mellitus (Gunton et 
al., 2005; Ravussin and Smith, 2002). 
An assay was developed to study the process of angiogenesis in human placental vein 
tissue, since rodent models may not predict the response of human disease (Gulec and Woltering, 
2004; Woltering et al., 2003).  This assay can also be used to test antiangiogenic drugs in a 
patient’s tumor before administering chemotherapy drugs, so the best drug can be matched to the 
individual patient and tumor.  We have modified this assay for use in human adipose tissue 
collected from abdominal surgeries (Greenway et al., 2005c).  This in vitro assay should better 
define the action of angiogenesis inhibitors in obesity since it uses human fat tissue. 
This assay takes surgically removed abdominal fat, cuts it into pieces approximately two 
millimeters cubed, and places them in 96 well plates embedded in a fibrin-thrombin clot.  After 
the clot has set for 24 hours, media is added in addition to any test compounds.  This media is 
changed every 48 hours, and an angiogenic index is calculated based on the amount of growth at 
each time point. 
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The tissue in each well is visually divided into four quadrants, the number of blood 
vessels sprouting directly from the fat mass is counted, and a score from one to four is given to 
each quadrant based on the number of vessels (Figure 1.1).  The sum of all the quadrants yields 
an index plotted over thirteen to fifteen days needed for the assay.  By this point significant 
angiogenesis will have occurred in the control group, and most of the endothelial growth will be 
in the initial phases of vascular development.   
 
 
Figure 1.1: Endothelial Vessel Growth in an Angiogenesis Assay.  Used with the permission 
of Frank Greenway. 
 
The decrease in body weight seen in obesity experiments with angiogenesis inhibitors 
seems to contradict the mechanisms involved in angiogenesis.  When the angiogenesis inhibitors 
are used, one might surmise that development of adipose tissue would cease, and other 
mechanisms would have to be employed to reduce the fat mass.  However, there are several 
current hypotheses as to why the drastic reduction in fat mass is seen.   
The most likely explanation is that the endothelial cells seen in adipose tissue are 
constantly susceptible to vascular remodeling and are programmed to initiate apoptosis unless 
the interstitial hormonal environment remains favorable for growth or stability (Rupnick et al., 
2002).  This hypothesis would suggest that adipose tissue endothelial cells remain in a constant 
         Angiogenesis                      Partial Inhibition                           Total Inhibition 
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immature state compared to other weight stable organs.  Consequently, the adipose tissue could 
rapidly expand or contract based on the prevailing metabolic needs of the organism.  This would 
also explain why adipose tissue is capable of growing so rapidly when other tissues remain 
totally weight stable. 
Many factors other than hypoxia are capable of altering the angiogenic capacity of 
adipose tissue.  There are hormones secreted by the adipose tissue itself, and other hormones 
secreted by the hypothalamus and intestine (Vettor et al., 2005).  There is an intricate process of 
stimulation and inhibition that must be tightly controlled by the tissue.  In fact, it is not only the 
adipocytes that help regulate this process, but also the adipose stromal cells that make up the 
connective tissue surrounding the fat cells.  These two tissues secrete factors that assist in 
breaking down tissue barriers and promote the propagation of endothelial cells through the 
tissue. 
The first of these factors, matrix metalloproteinases (MMPs), are enzymes that degrade 
the extracellular matrices surrounding the fat tissue (Hausman and Richardson, 2004).  This, in 
effect, prepares the tissue to be penetrated by new cells.  In most tissues, including adipose 
tissue, there is extremely tight regulation on the molecules and cells that leave the vasculature 
and enter the tissue.  The MMPs help facilitate the entry of new endothelial cells into adipose 
tissue by loosening the grasp of the matrix on fat cells. 
The plasminogen enzymatic system also is another class of enzymes that participates in 
the stimulation of angiogenesis.  These enzymes help to break down the basement membrane 
surrounding the vasculature separating the artery from the adipose tissue (Hausman and 
Richardson, 2004).  Endothelial cells are connected by tight junctions, which allow only the 
smallest nutrients and particles through.  Endothelial cells are further encapsulated by a basement 
membrane which prevents unwanted cells from penetrating the tissue.   
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This system is modulated by plasminogen activator inhibitor-1 (PAI-1), and high PAI-1 
levels are associated with hypercoagulability.  Mice with mutations in the PAI-1 gene have 
shown decreases in adipose endothelial cells, but interestingly no decrease in adipose mass or 
development (Hausman and Richardson, 2004).  Although it can be assumed that this is due to a 
primary effect of PAI-1 on the vasculature, there must be additional underlying mechanisms that 
are affecting this system. 
The two factors discussed above are vital in allowing the vasculature to develop, but 
there must be a signal that stimulates their secretion more reliably than insulin or a lack of leptin.  
Indeed there is, and this compound is called vascular endothelial growth factor (VEGF).  VEGF 
is the principal factor that controls angiogenesis in adipose and many other tissues.  Its secretion 
causes a chain of events the severity of which depends on the amount of VEGF secreted (Claffey 
et al., 1992). 
VEGF is a protein whose expression is stimulated by protein kinase C- and A- mediated 
pathways (Claffey et al., 1992).  In endothelial cells, it is the action of VEGFR-2 receptor that 
plays a pivotal role in modulating the physiological and pathological changes associated with 
angiogenesis induction (Fukumura et al., 2003).  Angiogenesis induction causes the activation of 
the MMPs and PAI-1, which result in angiogenesis.  VEGF is positively correlated with BMI 
and visceral fat in addition to the induction of angiogenesis (Miyazawa-Hoshimoto et al., 2003). 
 Many other hormones help regulate this process, and the mechanisms of several are still 
not fully understood.  What is clear at this point is that inhibiting angiogenesis in rodents leads to 
a chain of events that result in weight loss and reliable weight maintenance.  Although the 
compounds most effective in rodents have been discussed, these compounds do not always 
inhibit angiogenesis in humans.  However, gallic acid inhibits angiogenesis in rodents and in 
human assays in vitro (Greenway et al., 2005b; York et al., 2005). 
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Nt and Gallic Acid 
 Nt, a traditional Chinese medicinal herbal supplement containing rhubarb, has long been 
used in China to help treat and prevent obesity.  Nt is made by soaking the leaves and roots of 
five herbs, freeze drying the liquid to a solid and using the solid as the supplement.  The makeup 
of this herbal decoction is 40% rhubarb root and stem, 13.3% astragalus root, 13.3% red sage 
root, 26-27% tumeric, and 6-7% dried ginger.  It was delivered orally in capsules during the 
human trials. 
Nt in Chinese studies caused weight loss in rats when orally gavaged.  In three separate 
experiments obese rats lost an average of 30-40% of their weight compared to the untreated 
controls.  Large drops in triglycerides, total cholesterol, and LDL cholesterol were seen, 
accompanied by an increase in HDL cholesterol (unpublished data; (Greenway et al., 2005b).  
These encouraging preliminary results were confirmed in the United States. 
 York et al performed a two month weight loss study in Wistar rats prior to the use of Nt 
in human clinical trials (York et al., 2005).  Two doses of Nt were studied along with a positive 
control (fenfluramine), a pair-fed group, and the saline-treated control.  The experimental and 
pair- fed groups gained between 25% and 35% less body weight compared to the controls, 
validating the Chinese studies and showing that Nt’s mechanism of action lies in decreasing food 
intake.  No adverse effects were seen with the exception of occasional loose stools, supporting 
the safety of Nt and encouraging initiation of a clinical trial. 
 A two month human pilot trial was performed by Greenway et al to examine the effects 
of Nt on food intake and body weight (Greenway, 2005).  The doses of Nt given were 1/6 and 
1/12 the doses given to the rats in the previous study, as converted using Kleiber’s 0.75 mass 
exponent equation (Heusner, 1982).  The treated groups did not show any significant change in 
food intake or weight loss, presumably due to the low doses employed.  Unfortunately, there 
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were treatment emergent adverse events related to loose stools.  These gastrointestinal side 
effects were most likely associated with the sennosides found in the herbal extracts.  These side 
effects prevented using higher doses of Nt in humans. 
 Concurrently with these experiments, an active ingredient in Nt was identified.  Through 
successive fractional and mass spectrometry, gallic acid was found to be an active compound in 
rhubarb, the main ingredient in Nt (unpublished data).  Gallic acid is found in many other herbs 
as well, and has been shown in rat studies to inhibit food intake (Glick, 1981; Liu et al., 2005) 
and in vitro to inhibit angiogenesis (Liu et al., 2005).  When rhubarb and Nt were tested in the 
angiogenesis assay described earlier, both were potent angiogenesis inhibitors.   
 The mechanism of action by which Nt causes weight loss was not clear, until 
angiogenesis inhibition was demonstrated.  Several experiments in the 1960s through the 1980s 
studied oral and parenteral gallic acid in rats (Glick, 1981; Glick and Joslyn, 1970b; Joslyn and 
Glick, 1969; van der Heijden et al., 1986).  The consistent finding in these studies was the 
reduction in food intake during the first several days of treatment.  The rats given gallic acid 
gained less weight than the control group, but the weight gain in both groups increased in 
parallel. 
 Several early studies of gallic acid in rodents raised concerns regarding anemia and liver 
toxicity in the rats.  Thus, a formal toxicology study was needed to demonstrate that the 
decreased food intake was not due to illness induced by gallic acid.   
 Studies were performed in 2001 in both mice and rats demonstrating the no observed 
adverse event level (NOAEL).  There was an absence of carcinogenicity or toxicity at doses 
effective in decreasing food intake (Niho et al., 2001; Rajalakshmi et al., 2001).  These studies 
were consistent with the studies in rats done by York et al.  A dose-response curve of gallic acid 
on angiogenesis was performed using the angiogenesis assay previously described.  Gallic acid 
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completely inhibited angiogenesis at 10-3 M (Greenway et al., 2005b).  Partial inhibition was 
seen at 10-4 M. 
 Since the human pilot study by Greenway et al was unable to provide efficacious levels 
of Nt without side effects, the first goal of this thesis is to initiate a human trial to study Nt in 
combination with additional gallic acid.  This should curb any increase in side effects, since 
gallic acid lacks the sennosides seen in Nt.  Research involving gallic acid given in tea has 
shown that the level absorbed reaches 10-6 M, which would presumably be increased to effective 
levels by giving several log orders more of gallic acid (Shahrzad et al., 2001).  Delivery of 
effective levels of gallic acid should be accompanied by a decrease in food intake and body 
weight. 
 The pharmacokinetic profile of gallic acid will also be examined as the second phase of 
this study.  This will give definitive data concerning the absorption rate and serum levels of the 
gallic acid using timed blood draws and urine collection.  Knowing the pharmacokinetics will 
determine optimal dosing and insure that toxic build-up of gallic acid will not occur. 
Gallic Acid and Colchicine 
 Another possible strategy for therapeutic use of gallic acid would be to combine it with 
other compounds known to inhibit angiogenesis by a different mechanism.  This will be the 
second focus of this thesis.  Such a combination of antiangiogenic drugs could be synergistic and 
a more effective treatment of angiogenesis driven diseases.  Based on blood vessel morphology 
in the assay using human fat, colchicine inhibits angiogenesis by a mechanism different than 
gallic acid (Chen et al., 2003; Levy et al., 1991).  Thus, the combination of colchicine and gallic 
acid may be a superior treatment for angiogenesis-driven diseases. 
 Colchicine is an alkaloid extracted from a plant grown in Asia Minor.  It has been used to 
treat a variety of diseases including liver cirrhosis, Mediterranean fever, and scleroderma 
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(Thomas et al., 1989).  Colchicine has also been used continuously for the treatment of gout 
since the sixth century.  Colchicine inhibits microtubule formation in cells that rely on complex 
intracellular structures to survive, including endothelial cells (Levy et al., 1991).  Microtubule 
inhibition halts the elongation of endothelial cells, resulting in a breakdown of the intracellular 
and extracellular matrix. 
 While this effect may seem detrimental, there are diseases that can be controlled by this 
inhibition at concentrations that do not adversely affect healthy tissue.  One such condition is 
psoriasis, where the epidermal tissue differentiation cycle time is reduced, resulting in increased 
tissue density and thickness (Kaidbey et al., 1975).  Thick scaly patches of skin develop on the 
body with increased redness due to angiogenesis supplying the newly formed cells with oxygen 
and nutrients. 
 Colchicine has been used with some success in treating psoriasis as an ointment rather 
than orally or intravenously.  Topical colchicine administration avoided side effects such as 
nausea, vomiting, or abdominal cramping associated with oral parenteral use (Kaidbey et al., 
1975).  The most effective dose of colchicine in these studies was a 1% concentration in a 
hydrophilic ointment, although hydrophilic petrolatum based ointments worked nearly as well. 
 The purpose of combining gallic acid and colchicine into a topical ointment is to inhibit 
angiogenesis by two different mechanisms.  The gallic acid will act by inhibiting the recruitment 
and proliferation of the endothelial cells, while the colchicine will stop microtubule formation 
and adhesion capability within these cells.  This dual action may result in the ability to use these 
herbal extracts at lower concentrations than what would be needed for treatment with either used 
alone.  This potential synergism may widen the therapeutic potential of angiogenesis inhibitors. 
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CHAPTER 2 
THE SAFETY AND EFFICACY OF A DIETARY HERBAL SUPPLEMENT AND 
GALLIC ACID FOR WEIGHT LOSS 
 
Introduction 
 
Nt is an herbal supplement derived from a water extract of 40% rhubarb root and stem 
(radix et rhizoma rhei), 13.3% astragulus root (radix astragali), 13.3% red sage root (radix 
salviae miltiorrhizae), 26-27% turmeric (rhizoma curcumae longae), and 6-7% dried ginger 
(rhizoma zingiberis officinalis).  Nt caused weight loss and reduced weight gain in rodents in 
China (Wei K, 2003). and its ability to suppress weight gain in rodents was confirmed by York et 
al. in the USA (York et al., 2005). 
A pilot study testing the efficacy and safety of Nt to induce weight loss in humans 
produced diarrhea as a result of sennosides, herbal laxatives present in the Nt, but was otherwise 
well tolerated (Greenway, 2005).  Nt was demonstrated to also contain gallic acid, a compound 
known to give weight loss and reduce food intake in rodents when given either orally or 
parenterally (Glick, 1981).  Therefore, in an effort to reduce the side effects of Nt and preserve 
weight loss efficacy, a mixture of Nt (20% by weight) with herbal gallic acid derived from gall 
nuts (80% by weight) was tested for safety and efficacy in treating human obesity.    
Gallic acid is generally recognized as safe (GRAS) in the form of gallotannins by the 
FDA and has been used as an antioxidant in food.  Toxicology studies in rodents show that the 
no-observed-adverse-effect- level (NOAEL) is 120 mg/kg, a dose equivalent to 2.9 grams in a 70 
kg man (Niho et al., 2001).  Gallic acid is available from herbal sources that can be used to 
increase the concentration in Nt.  The human equivalent amount of gallic acid in the low dose of 
Nt shown to be effective for weight loss in rodents is 1.2 grams per day, less than half the 
NOAEL (Heusner, 1982).  
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An 8-week pilot study was performed at the Pennington Center in eight healthy females 
with a BMI between 25 and 35 kg/m2 on no regular medications except birth control or hormone 
replacement therapy.  Subjects were randomized to two placebo capsules three times a day or 
two capsules each containing 200 mg of gallic acid from an herbal source and 50 mg of crude Nt 
extract given three times a day, for a total of 1.2 grams of gallic acid and 300 mg of crude Nt 
extract per day.  This dose of gallic acid was less than 50% of the NOAEL and the amount of Nt 
was only 5% of the dose shown to give loose stools.  Weight loss in the Nt-gallic acid group was 
3% of body weight compared to 1.8% in the placebo group (p=0.38).  Compliance by pill count 
was >98% and there were no significant changes in blood pressure, pulse, complete blood counts 
or chemistry panel values throughout the trial.  There were no adverse events felt to be related to 
the treatment and there were no changes in the physical examinations or electrocardiograms.  
Results of the pilot study were used to power a 6-month clinical trial testing the safety 
and efficacy of two doses of the Nt-gallic acid mixture.  One dose was the same as that used in 
the pilot trial, i.e. 1.2 grams of gallic acid per day, and the second dose contained 2.4 grams of 
gallic acid per day, below the 2.9 grams per day determined to be the NOAEL calculated from 
the metabolic mass equation using the data from rats (Heusner, 1982).   
Materials and Methods 
Main Study Design 
One hundred five healthy volunteers between the ages of 18 and 60 years of age with a 
BMI between 25 and 35 kg/m2, on no chronic medication other than oral contraceptives or 
hormone replacement therapy, participated in this 24-week study.  Subjects had height, weight 
and blood pressure measured, pulse taken, and a CBC (hemoglobin, hematocrit, mean 
corpustular volume, platelets, white blood cell count, neutrophil number, and eosinophil number) 
and chemistry panel (creatinine, uric acid, potassium, glucose, albumin, calcium, magnesium, 
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iron, creatine phosphokinase, alanine leucine transaminase, alkaline phosphatase, total 
cholesterol, triglycerides, high density lipoprotein cholesterol, and low density lipoprotein 
cholesterol) done at screening.  A registered dietitian at baseline instructed subjects in a diet 700 
kcal/d below weight maintenance requirements based on the World Health Organization formula 
(World Health Organization, 1990).  At baseline, an electrocardiogram, medical history and 
physical examination were done, and women had a pregnancy test performed.   
Subjects were randomized to two doses of an Nt mixture (20% Nt and 80% gallic acid) or 
placebo.  The Nt enriched with gallic acid was given at either 1.2 grams of gallic acid and 300 
mg of Nt per day or at 2.4 grams of gallic acid and 600 mg of Nt per day vs. placebo in a 1:1:1 
ratio.  Capsules contained 200 mg of gallic acid and 50 mg of Nt or placebo.  Subjects took 2 
capsules 3 times a day.   On each visit (weeks 0, 2, 4, 8, 12, 16, 20, and 24), subjects were 
weighed, had their blood pressure measured, their pulse taken, their medications dispensed, 
medication bottles returned, and subjects were questioned about any adverse events.  The 
physical exam, CBC, chemistry panel, pregnancy test and electrocardiogram were repeated on 
week 24 at the end of the study.  
Food Intake 
Subjects had food intake evaluated with a universal eating monitor at screening and at 
week two of the study.  Subjects visited the food intake laboratory after an overnight fast during 
which only water was allowed.  Subjects completed Visual Analogue Scales (VAS) of appetite 
and a questionnaire about factors that might affect taste such as colds or allergies. They were 
then given 2 pills to swallow and the VAS was repeated after 1 hour.  An hour after receiving the 
pills the subjects were given a meal of sandwich quarters, chips, and cookies larger than they 
could reasonably eat, and they were allowed to eat as much or as little as they wished for 20 
minutes.  At the completion of the meal, subjects completed the VAS again to conclude a pre- 
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and post-meal evaluation.  The subjects were given placebo on the first visit and the treatment to 
which they were randomized on week 2.   
Pharmacokinetic Sub-Study 
Five healthy men between the ages of 18 and 60 years with a BMI between 20 and 35 
kg/m2 were enrolled.  The subjects took no regular medication and were not lactose intolerant.  
Subjects had a medical history, physical examination and chemistry panel performed at 
screening.  All subjects received a gallic acid-free diet of white bread, cheese, butter, and water 
or milk for the day prior to and the day of each pharmacokinetic test lasting through the end of a 
24 hour urine collection.   
The first two subjects had two pharmacokinetic tests one week apart.  The first subject 
had one test with gallic acid from gall nut extract 800 mg after an overnight fast and the other 
test was with gallic acid from gall nut extract 800 mg along with a 570 kcal meal consisting of a 
grilled cheese sandwich and a glass of milk.  The second subject had one test with gall nut 
extract 800 mg combined with Nt 200 mg after an overnight fast and the other test was with 
gallic acid from gall nut extract 800 mg combined with Nt 200 mg along with the same 570 kcal 
meal.  The mixture of 800 mg gallic acid from gallnut extract and 200 mg Nt was the same as the 
high dose of the Nt-gallic acid mixture used in the trial.    
Subjects reported fasting on the morning of the test and took test medication orally.  Ten 
cc blood samples were collected at times 0, 30, 60, 90, 120, 150, 180, 240, 360, and 480 minutes.  
The blood was collected in heparinized tubes, centrifuged, plasma separated and frozen until 
analyzed on high-pressure liquid chromatography (HPLC) for gallic acid and gallic acid 
metabolites.   
The second two subjects had one test day after an overnight fast with gallic acid from gall 
nut extract 800 mg without a meal.  The fifth subject had one test day after an overnight fast in 
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which he let 800 mg of gallic acid from gall nut extract contained in hard candy dissolve in his 
mouth.  All subjects emptied their bladders at time 0, and an aliquot of the urine was frozen for 
later analysis.  All urine was collected for the 24 hours following the gallic acid ingestion.  The 
urine volume was measured and an aliquot was frozen for later measurement of gallic acid and 
gallic acid metabolites. 
Statistics 
The study was designed to extend over 24 weeks with interim analysis at 8 weeks.  Thus, 
the study was powered for two endpoints, the interim endpoint at 8 weeks and the 24-week 
endpoint.  The first power calculation for the 8-week time point was based on a standard 
deviation of 4 kg, a value derived from Pennington weight loss studies at 8 weeks.  Since the 
expected difference between the 2.4 gram gallic acid group and placebo was 3 kg at 8 weeks 
based on the pilot study, there was an 80% power to detect this difference at 8 weeks with 29 
subjects finishing in each group at p<0.05.  Allowing for a 20% dropout rate, one needed to 
enroll 35 subjects per arm. 
The second power calculation was for the 24-week time point and was based on a 
standard deviation of 6.5 kg, a value derived from Pennington weight loss studies at 24 weeks.  
Since the expected difference between the 2.4 gram gallic acid group and placebo was 5 kg at 24 
weeks based on the pilot study, there was an 80% power to detect this difference at 24 weeks 
with 28 subjects finishing in each group at p<0.05.  Allowing for a 20% dropout rate, one needed 
to enroll 35 subjects per arm. 
Repeated measures analysis of variance was used to compare weight loss in the Nt-gallic 
acid and placebo groups.  The interim analysis was performed at 8 weeks and a final analysis at 
24 weeks.  The primary study endpoint was body weight.  Secondary endpoints were food intake 
and the safety measures (laboratory, adverse events and electrocardiograms).   The study was 
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powered to detect a 3 kg difference at 8 weeks and a 5 kg difference at 24 weeks at 80% power 
with an alpha of 0.05.  
Results 
Efficacy 
Weight Loss 
The planned interim analysis was performed at 8 weeks.  Baseline weights in the placebo, 
low dose and high dose groups were 83.3 + 2.05 kg (SEM), 84.1 + 2.53 kg, and 82 + 2.18 kg 
respectively.  The placebo group behaved as expected with an average weight loss of 0.7% body 
weight (0.6 + 0.42 Kg, SEM).  Subjects receiving the low dose Nt-GA mixture (1.2 gm Nt – 300 
mg gallic acid) lost 1.2% body weight (2.6 + 1.3 kg) that was statistically different than placebo 
(p<0.05).  Subjects on the high dose Nt-GA mixture (2.4 gm Nt - 600 mg gallic acid) lost 0.6 % 
body weight (0.46 + 0.74 kg), an amount that was not different from placebo.  
After all subjects were enrolled, the interim analysis showed no evidence of efficacy, so 
the trial was terminated.  Thus, the number of subjects completing the trial was less than 
anticipated.  At the end of 24 weeks, there were 19 subjects in the high dose group, 20 subjects in 
the low dose group and 25 subjects in the placebo group.  The final weight loss at 24 weeks was 
1.05 + 0.54 (SEM) kg in the placebo group, 2.01 + 1.18 kg in the low dose group and a gain of 
0.54 + 0.79 kg in the high dose group.  The difference between the high and low dose groups was 
statistically significant (p = 0.044), but weight loss in the Nt-GA groups was not significantly 
better than placebo (Figure 2.1).  
Food Intake 
Food intake was measured in the eating laboratory at Weeks 0 and 2.  One-way analysis of 
variance (ANOVA) indicated that the three groups’ food intake (kcals) did not differ 
significantly at Week 0, F(2, 102) = 1.37, p = 0.26.  Dependent t-tests indicated that food intake 
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(kcals) decreased significantly from Week 0 to Week 2 for the high dose group only, t(32) = 
2.33, p < 0.05.  Nevertheless, independent samples t-tests indicated that the food intake 
difference scores (food intake at Week 2 minus Week 0) did not differ between the placebo and 
low dose group, t(70) = -0.39, p = .70, or the placebo and high dose group, t(67) = 67, p = .73.  
The change in food intake from Week 0 to Week 2 by group is illustrated in Figure 2.2. 
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Figure 2.1.  Nt–Gallic Acid 24-Week Weight Loss. 
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Figure 2.2.  Change in Food Intake (kcals) from Week 0 to Week 2 by Group. 
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Safety 
Blood Pressure and Pulse Rate 
Systolic blood pressure rose 1.9 + 2.3 (SD) mm Hg in the placebo group, 1.7 + 2.1 mm 
Hg in the high dose group and fell 1 + 1.8 mm Hg in the low dose group.  Diastolic blood 
pressure rose 1.9 + 1.5 mm Hg in the high dose group, 0.43 + 1.9 mm Hg in the low dose group 
and 0.8 + 1.3 in the placebo group.  The pulse rate rose 2.6 + 2.5 bpm in the high dose group, 3.2 
+ 2.4 bpm in the low dose group and 1.0 + 1.9 in the placebo group.  None of these differences 
were statistically significant. 
Complete Blood Counts, Chemistry Panel, Liver Function and Lipids 
  Hemoglobin and hematocrit fell significantly in the high dose Nt-gallic acid group 
compared to the placebo group: -0.51 + 0.21 vs. -0.02  + 0.12 gm (SEM) and –1.9 + 0.6 vs. -0.62 
+ 0.65 % respectively (p<0.05).  Uric acid dropped more in the high dose group than in the low 
dose or placebo groups; -0.71 + 0.24 vs. –0.05 + 0.12 vs. -0.16 + 0.12 mg/dL respectively 
(p<0.05).  There were no other dose related changes in the laboratory testing.  These laboratory 
values were fluctuations within the normal range and none of the changes were clinically 
significant.  
Compliance 
Pill counts showed that the subjects in the low dose group took 94.8 + 0.8%, subjects in 
the placebo group took 93 + 0.8% and the subjects in the high dose group took 92.2 + 1.5% of 
the pills prescribed.  These compliance numbers did not differ between the groups.  
Pharmacokinetics  
The subject who took Nt-gallic acid (200 mg – 800 mg) on two occasions, once fasting 
and once with food had a peak gallic acid concentration in the plasma of 10 uM without food at 4 
hours and a peak plasma concentration of 8 uM with food at 2 hours (Figure 2.3).   The subject 
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who took gallic acid 800 mg on two occasions, once fasting and once with food had a peak gallic 
acid concentration in plasma of 2 uM without food at 2 hours and a peak plasma concentration of 
7 uM with food at 4 hours (Figure 2.4).   The three subjects who had 800 mg of gallic acid orally 
when fasting had a peak plasma concentration of gallic acid in the plasma of 4 uM at 2.5 to 3 
hours (Figure 2.5).  The one subject who let candy containing 800 mg of gallic acid dissolve in 
his mouth fasting had a peak plasma concentration of gallic acid of 9 uM at 2 hours (Figure 2.6).  
Measurement of gallic acid in the urine revealed that the capsules of gallic acid with or without 
Nt had about 6% absorption.  Eating increased absorption to the 9-12% range.  By allowing for 
complete dissolution and allowing for possible trans-mucosal absorption using candy containing 
gallic acid dissolved in the mouth increased absorption further to 19% (Figure 2.7).   
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Figure 2.3.  Gallic Acid-Nt With and Without Food.  Gallic Acid 800 mg with Nt 200 mg 
with and without Food in 1 subject on 2 occasions. 
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Figure 2.4.  Gallic Acid With and Without Food.  Gallic Acid 800 mg with and without food 
in one subject on two occasions. 
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Figure 2.5.  Oral Administration of Gallic Acid.  Serum levels of gallic acid in three subjects 
after oral ingestion of 800 mg. 
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Figure 2.6.  Gallic Acid Administered in Candy.  Serum levels of gallic acid in one subject 
after letting candy with 800 mg of gallic acid dissolve in the mouth fasting. 
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Figure 2.7.  The Percent of Gallic Acid Absorbed Orally.  The percent absorption of Gallic 
Acid from the gastrointestinal tract and the effect of food on absorption. 
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Discussion 
When gallic acid was fed to rats at levels of 2%, 4%, 5%, 6%, 8% and 10% of diet, food 
intake was depressed and there were no deaths up to 5% of the diet.  At 5% of diet, gallic acid 
depressed food intake by 50% with a similar reduction in body weight compared to control 
(Joslyn and Glick, 1969).  There was a marked increase in hepatic fat in rats fed a diet with 5% 
gallic acid, 36% vs. 7% of dry weight, which was not seen with similar levels of tannic acid 
(Glick and Joslyn, 1970b).  Fecal protein excretion increased with feeding of the diet 
supplemented with tannic acid, but was not significantly different from control with diets 
supplemented with gallic acid (Glick and Joslyn, 1970a).  Gallic acid was also shown to decrease 
food intake when infused intraperitoneally as a 2% solution.  Thus, the mechanism by which 
gallic acid decreases food intake involves more than taste aversion or gastrointestinal factors 
(Glick, 1981).   
These studies with gallic acid along with evidence that Nt contained gallic acid 
encouraged us to explore the use of herbal gallic acid combined with Nt for the treatment of 
obesity in humans.  The no observed adverse effect level (NOAEL) in rodents is 120 mg/kg, a 
dose equivalent to 2.9 grams per day in a 70 kg man using the metabolic mass equation 
(Heusner, 1982; Niho et al., 2001).  The daily doses of the herbal gallic acid used in this study 
were up to 2.4 grams, well below the NOAEL in these obese subjects.  The doses of Nt used in 
this study did not exceed 600 mg, one tenth of the dose that gave loose stools in a clinical trial of 
Nt. 
The Nt-gallic acid mixture was well tolerated and loose stools were not a problem.  
Disappointingly, the combination did not give weight loss.  In fact, the high dose gave less 
weight loss than the placebo.  This was surprising in view of the experience in rodents in which 
food intake was suppressed.   
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A human pharmacokinetic study of gallic acid by Shahrzad et al. demonstrated that 40% 
of a 50 mg dose of gallic acid was absorbed and achieved a peak serum concentration between 
1.8 and 2.1 micromolar (1.8-2.1 times 10-6 molar) at 1 hour and 10 minutes (Shahrzad et al., 
2001).  We developed an HPLC method to measure gallic acid and did pharmacokinetic studies 
with the high dose of Nt-gallic acid (Nt 200 gm and gallic acid 800 mg) and with the gallic acid 
it contained.  Only 6% was absorbed giving a peak serum concentration of 4 micromolar (4 times 
10-6 molar).   Food appeared to increase absorption, and letting hard candy containing 800 mg of 
gallic acid dissolve in the mouth further increased absorption.    
Even in the best of circumstances the absorption never exceeded 19% and the plasma 
levels never exceeded 10 micromolar (10 times 10-6 molar).  This suggests, but does not prove, 
that gallic acid absorption is limited in humans by an active transport system that becomes 
saturated far below the levels needed to get levels of gallic acid into the plasma that are adequate 
to suppress food intake.  
   Unfortunately, the Nt - gallic acid pilot data that looked so encouraging for weight loss 
appears to have been misleading due to the small numbers of subjects which precluded obtaining 
a statistically significant result.  The information generated by this trial is still important to 
report.  The animal data were very encouraging that gallic acid would be effective and safe for 
weight loss, and it is likely that someone else would have explored this possibility.  This trial 
gives evidence that gallic acid will not be an effective oral supplement for the treatment of 
human obesity.    
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CHAPTER 3 
GALLIC ACID AND COLCHICINE INHIBIT ANGIOGENESIS SYNERGISTICALLY 
  
Introduction 
 
Colchicine, a tubulin inhibitor, inhibits angiogenesis at 10-8 M and higher concentrations 
(Stafford et al., 2005).  Gallic acid is another inhibitor of angiogenesis derived from gallotannins 
which are natural plant products (Liu et al., 2005).  Gallotannins inhibit angiogenesis by 
blocking the effect of VEGF on endothelial cells (Lee et al., 2004).  4-O-methylgallic acid and 
the gallotannin, penta-O-galloyl-beta-D-glucose inhibit the angiogenesis stimulated by basic 
fibroblast growth factor in addition to blocking endothelial cell VEGF production (Huh et al., 
2005; Jeon et al., 2005).  Tannic acid also selectively inhibits the interaction of CXCL 12/stromal 
cell-derived factor-1 alpha with its receptor, CXCR4, an interaction that participates in 
angiogenesis (Chen et al., 2003).  Thus, since these two inhibitors act through different 
mechanisms, combining them might be synergistic or additive for inhibiting of angiogenesis.  
We hypothesize that gallic acid and colchicine will inhibit angiogenesis when combined. 
  
Materials and Methods 
Tissue Preparation 
 Fat removed at surgery was cut into fragments approximately 1 mm thick and 2 mm in 
diameter.  These fat fragments were placed in 96-well plates as described below.   
Preparation of the 96-well Plates 
 The 96-well plates were loaded with human thrombin solution (0.05 IU in 4mcL/well).  
Loading the 96-well Plates 
 The fat fragments were placed in the prepared 96-well plates and covered with 100 µl 
clotting media.  The clotting media consisted of fibrinogen (3 mg/ml) (Sigma Chemical Co., St. 
Louis, Missouri) and epsilon amino caproic acid (0.5%) (Sigma Chemical Co., St. Louis, 
 30 
Missouri) in human placental vein angiogenesis model (HPVAM) media.  HPVAM media 
consists of Medium 199 (GibcoBRL, Gaithersberg, Maryland), and antibiotic/antimycotic 
solution (100 U penicillin, 100 U streptomycin sulfate and 0.25 mcg amphotericin beta per ml) 
(GibcoBRL, Gaithersberg, Maryland).  The mixture was allowed to clot by incubation in 6% 
CO2, 94% air at 37oC in a humidified incubator.  After the media had gelled overnight, the fat-
containing clot was supplemented with 100 mcL HPVAM media containing 20% fetal bovine 
serum (GibcoBRL, Gaithersberg, Maryland).  The total volume of each well was 200 mcL. 
Angiogenic Evaluation 
 All wells were evaluated for angiogenic sprouting by examination at 40X and 200X 
magnification by an unbiased observer using an inverted microscope on Mondays, Wednesdays, 
and Fridays.  Angiogenesis was defined by two criteria.  First, the number of wells (as a 
percentage of the total plated) that developed new vessel growth was termed initiation.  This was 
defined by the presence of at least three angiogenic sprouts of approximately 0.5 mm in length 
growing from the periphery of the fat tissue.  The degree of angiogenic response was assessed 
using a semi-quantitative visual rating scale (Bosman, 1994).  The tissue was visually divided 
into four quadrants.  Each quadrant was given a numeric score from 0-4 based on the neovessel’s 
length, density and percentage of the quadrant’s circumference involved with the angiogenic 
response.  Numeric results from the four quadrants were summed and expressed as an angiogenic 
index (AI, 1-16).  This rating scale has been validated by Hornick et al using multiple 
independent observers (Hornick et al., 2003).  
Experiments 
Colchicine was tested at concentrations of 10-5, 10-6, 10-7, 10-8, 10-9, 10-10 and 10-11 M.  
Gallic acid was tested at concentrations of 10-2, 10-3, 10-4, 10-5 and 10-6 M.  Colchicine and gallic 
acid in combination were tested at the concentrations of colchicine 10-9 M with gallic acid 10-4 
 31 
M, colchicine 10-10 M with gallic acid 10-5 M, and colchicine 10-11 M with gallic acid 10-6 M, 
since these concentrations were physiologically acheivable. 
Results 
Preliminary assays showed that the optimal concentration for colchicine to test for 
synergism was 10-10 M and gallic acid 10-5 M.  These concentrations, when combined, were 
partially inhibitory compared to combinations of colchicine 10-9 M and gallic acid 10-4 M, which 
were completely inhibitory, and colchicine 10-11 M and gallic acid 10-6 M, which did not inhibit 
angiogenesis compared to the control.  Using intermediate concentrations allowed a better 
interpretation of possible synergism, since each concentration alone was able to block 
angiogenesis compared to the control, but the combination did not result in complete inhibition.  
In addition, higher levels of colchicine resulted in beading of the blood vessels in the assay, 
possibly leading to eventual tissue injury (Figure 3.1).  This beading was not seen at inhibitory 
concentrations of gallic acid, another indication that these two compounds had different 
mechanisms by which they inhibited angiogenesis. 
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Figure 3.1.  Vascular Beading Caused by Colchicine. 
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The results of the assay in which colchicine, gallic acid and the combination was 
compared to control is shown in Figure 3.2.  Colchicine 10-10 M inhibited angiogenesis 31% 
compared to the control, while gallic acid 10-5 M inhibited angiogenesis 50% compared to the 
control.  Consequently, if a strictly additive effect were to be seen, the combination group would 
give an 81% reduction in angiogenesis.  However, the combination of colchicine 10-10 M and 
gallic acid 10-5 M inhibited angiogenesis by 91% compared to the control, indicating that these 
two angiogenesis inhibitors act in a synergistic rather than a strictly additive manner. 
 
 
 
 
 
 
 
 
  
 
Figure 3.2.  Colchicine and Gallic Acid Inhibit Angiogenesis Synergistically.   
 
Discussion 
As hypothesized, colchicine and gallic acid were synergistic in inhibiting angiogenesis.  
Angiogenesis plays a role in the etiology of many diseases, and is involved in the pathogenesis 
of psoriasis (Leong et al., 2005).  In fact, topical colchicine has been used as a treatment for 
psoriasis (Kaidbey et al., 1975), and gallic acid has been included in topical psoriasis treatments 
as well (Bosman, 1994).   In fact, pilot work in our clinic with 0.2 M gallic acid cream gave 
resolution of long standing psoriasis lesions over 16 weeks (Figure 3.3).  Therefore, it is likely 
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that the combination of gallic acid and colchicine will be even more effective than either of the 
separate components, and since lower doses can be used in the combination, the potential for 
adverse events, which was low when the components were used separately, will be further 
reduced.   
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Figure 3.3. Psoriasis Area and Severity Index.  Psoriasis Area and Severity Index scores over 
16 weeks of topical treatment for bilateral psoriasis with 0.2 M gallic acid cream applied twice a 
day.   
 
Inhibitors of angiogenesis have been shown to reverse animal models of obesity (Rupnick 
et al., 2002).  Therefore, it is likely that local application of angiogenic inhibitors will cause 
localized fat reduction for cosmetic purposes.  If this is borne out in subsequent clinical trials, 
colchicine and gallic acid may be used for spot fat reduction in much the same way that creams 
containing beta-adrenergic stimulators have been used to reduce the size of the hips, thighs, waist 
and to smooth the skin of the buttocks and thighs in women (Caruso et al., 2005; Greenway et 
al., 1995). 
A pharmacokinetic study of oral gallic acid suggested that an 800 mg dose gives serum 
levels between 4 x 10-6 and 1 x 10-5 M without any sign of toxicity (Roberts et al., 2005c).  
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Colchicine doses between 0.5 and 1.5 mg, doses used routinely for the prevention of gout, give 
peak serum levels of approximately 1 x 10-6 M (Girre et al., 1989).  Therefore, it may be possible 
that the combination of gallic acid and colchicine in the concentrations shown to be synergistic 
in the fat assay could be achieved by oral administration in humans.  If this were so, the 
combination might represent a safe oral obesity drug for non-pregnant women.   
We conclude that gallic acid 10-5 M combined with colchicine 10-10 M inhibits 
angiogenesis synergistically.  This combination may be an effective topical treatment for 
angiogenesis driven diseases like psoriasis and possibly represent a safe oral treatment for 
angiogenesis driven diseases like obesity.   
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CHAPTER 4 
SUMMARY AND CONCLUSIONS 
Although initial animal data demonstrated the potential weight loss efficacy of Nt, 
subsequent human trials proved that Nt, even in combination with gallic acid, was not successful 
in decreasing food intake and body weight in humans.  The second phase of the human trial, as 
reported in this thesis, evaluated the pharmacokinetics of gallic acid.  When several forms and 
doses of gallic acid were given orally, the absorption rate never rose above 19%, indicating that 
the transport mechanism for gallic acid across the gastrointestinal tract in humans may be 
saturated.  This could explain why impressive weight loss was seen in rodents but did not carry 
into humans. 
Although methods to increase oral absorption of gallic acid may be available, additional 
research should be done to evaluate the saturation point of this mechanism.  If the system is 
indeed saturated, gallic acid may be more effective when given parenterally, although an 
indication for obesity would almost definitely be ruled out.  Preliminary reports have shown that 
gallic acid may have use in treating certain forms of cancer when given intravenously, however 
no formal studies have been performed in humans to validate this pilot data obtained in rodents. 
Another possible way to use gallic acid therapeutically is to combine it with other 
angiogenesis inhibitors that act through different mechanisms to increase the combined 
effectiveness through synergism.  This strategy was examined in the second research goal of this 
thesis when gallic acid was combined with colchicine in an in vitro assay.  The compounds, in 
combination, clearly showed greater inhibition of angiogenesis than either the control or each 
compound individually.  Using such a combination may circumvent the problems seen with 
transport saturation when using gallic acid alone.  More importantly, this study demonstrates that 
gallic acid and colchicine may have uses in other conditions driven by angiogenesis that do not 
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require intestinal absorption, psoriasis being one example.  More research should be done to 
develop a topical treatment for psoriasis with greater efficacy based on the synergistic interaction 
of gallic acid and colchicine to inhibit angiogenesis.   
 The original intent of this thesis was to evaluate the efficacy Nt and gallic acid in treating 
obesity.  As often happens in research, new information was discovered that may lead to 
treatments for diseases that currently lack adequate therapeutic alternatives.  These findings 
further validate the importance of research into angiogenesis and its mechanisms.  A better 
understanding of angiogenesis may lead to more effective treatment of conditions from cancer to 
obesity when inhibited, and revascularization after heart attacks or repair of tissue injury when 
stimulated.  Such wide ranging effects may address disease in multiple organ systems and benefit 
different diseases simultaneously, improving health and quality of life. 
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